Latest News
Update on Cure SMA Summit of Strength Program – Gearing Up for 2020!
The 2019 Summit of Strength Program was a huge success, with more than 135 speakers sharing their expertise on numerous highly rated and unique topics. We would like to thank […]
Read More ›Check Out the Cure SMA Booklet on “Scientific Considerations for Drug Combinations”
There are now two treatments approved by the U.S. Food and Drug Administration (FDA) that target the underlying genetics of spinal muscular atrophy (SMA) and several others in clinical trials. […]
Read More ›9th Annual “Hope on the Hill” Congressional Dinner
Just one more week until the 9th Annual “Hope on the Hill” Congressional Dinner in Washington D.C.! Next Tuesday, December 3rd, SMA families and advocates, government officials, and industry leaders […]
Read More ›Cure SMA and Genentech Partner to Provide Travel Support to Adults with SMA for the 2020 Annual SMA Conference
Cure SMA is thrilled to announce that we will, once again, be offering scholarship opportunities to adults with SMA (18 years of age and older) to attend the 2020 Annual […]
Read More ›Community Statement from Genentech: FDA Grants Priority Review to Risdiplam for Spinal Muscular Atrophy
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, […]
Read More ›SMA Concordance Among Siblings Published in the Journal of Neuromuscular Diseases
Earlier this month, an article was published in the Journal of Neuromuscular Diseases titled, “Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings from the Cure SMA Cohort.” This paper […]
Read More ›